Is Wegovy Safe for Weight Loss? Trusted Weight Loss Guidance Bishops Stortford

Is Wegovy Safe for Weight Loss? Trusted Weight Loss Guidance Bishops Stortford

Wegovy (semaglutide 2.4mg) is considered safe for weight loss in appropriately assessed adults, having received approval from both the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the European Medicines Agency (EMA) following rigorous clinical evaluation — and it is one of the most thoroughly studied weight loss medications ever brought to market. The STEP clinical trial programme, which underpins Wegovy’s licence for weight management, enrolled over 4,500 participants across multiple countries and demonstrated a consistent and favourable safety profile across diverse patient populations. Like all prescription medications, Wegovy carries a recognised list of side effects and contraindications that must be carefully assessed before treatment is initiated, and it is not appropriate for everyone — which is why a thorough clinical assessment before prescribing is not just recommended but legally required. The most commonly reported side effects are gastrointestinal in nature — nausea, vomiting, diarrhoea, and constipation — and are typically mild to moderate in severity and most pronounced in the early weeks of treatment. At J E Williamson Pharmacy in Bishops Stortford, ensuring every patient receives a thorough safety assessment before starting Wegovy, and has the clinical support needed to manage any side effects that arise, is central to the weight management care we provide.

The Evidence Base Behind Wegovy’s Safety

Wegovy’s safety profile is underpinned by one of the most comprehensive clinical trial programmes ever conducted for a weight management medication. The STEP (Semaglutide Treatment Effect in People with obesity) programme comprised several major randomised controlled trials evaluating semaglutide 2.4mg across different patient populations, including adults with obesity and no diabetes (STEP 1), adults with overweight or obesity and type 2 diabetes (STEP 2), adults who had already lost weight and were seeking to maintain it (STEP 4), and adolescents aged 12 to under 18 years with obesity (STEP TEENS). Across all arms of the programme, the safety monitoring was extensive — adverse events were systematically collected, adjudicated, and reported with a level of rigour that sets the evidence base for Wegovy apart from many other weight loss treatments. The MHRA reviewed this data in full before granting Wegovy’s UK licence for weight management, and the ongoing pharmacovigilance programme continues to monitor safety in real-world use.

Beyond the STEP trials, the SELECT cardiovascular outcomes trial — published in the New England Journal of Medicine in 2023 — provided compelling evidence of semaglutide’s safety and benefit in a high-risk cardiovascular population. SELECT enrolled over 17,000 adults with overweight or obesity and established cardiovascular disease but without diabetes, and found that semaglutide reduced the relative risk of major adverse cardiovascular events (MACE — non-fatal heart attack, non-fatal stroke, and cardiovascular death) by 20% compared to placebo — equivalent to an absolute risk reduction of approximately 1.5 percentage points — over a mean follow-up of more than three years. This landmark finding not only confirmed the safety of semaglutide in a large, high-risk population but demonstrated an active cardiovascular benefit that extends well beyond weight loss alone, significantly strengthening the clinical case for its use in eligible patients.

Common Side Effects of Wegovy

The most frequently reported side effects of Wegovy are gastrointestinal in nature and are well-characterised from the clinical trial data. Nausea is the most common, affecting a significant proportion of patients in the early weeks of treatment and following each dose increase, though it typically diminishes substantially as the body adjusts to the medication at each dose level. Vomiting, diarrhoea, constipation, abdominal discomfort, and reflux are also commonly reported and follow a similar pattern of being most pronounced in the early adjustment period and improving with time. In clinical trials, these side effects were the most common reason for treatment discontinuation, though the majority of patients who persisted through the initial adjustment period reported a considerably more comfortable experience at their established dose. Understanding the likely pattern of gastrointestinal side effects before starting treatment — and having clinical support readily available when they arise — significantly improves both tolerance and adherence.

Other commonly reported side effects include fatigue, headache, dizziness, and injection site reactions such as localised redness or bruising. These are generally mild and self-limiting, though fatigue in particular can be more pronounced in the early weeks of treatment, partly as a consequence of reduced calorie intake and the body’s metabolic adjustment to the medication. Practical strategies for managing gastrointestinal side effects include eating smaller, more frequent meals, avoiding high-fat or spicy foods during the adjustment period, staying well-hydrated, and taking the injection on a day when any post-dose symptoms can be managed with minimal disruption. The gradual dose escalation schedule of Wegovy — starting at 0.25mg and increasing over 16 weeks to the 2.4mg maintenance dose — is specifically designed to minimise side effect severity by allowing the body time to adapt at each dose level.

The clinical team at J E Williamson Pharmacy in Bishops Stortford is here to help every Wegovy patient manage side effects effectively and stay on course for the results the medication is capable of delivering.  Contact us today and put the right clinical support in place from the very beginning of your treatment.

Book now

Wegovy Side Effects by Frequency and Severity

The table below provides an overview of the most clinically important Wegovy side effects, categorised by their frequency and typical severity, based on the published clinical trial data and the approved Summary of Product Characteristics.

Serious Adverse Events

While the majority of patients on Wegovy experience only the common gastrointestinal side effects described above, there are a small number of more serious adverse events that patients and clinicians need to be aware of. Pancreatitis — inflammation of the pancreas — is listed as an uncommon adverse event in the Wegovy SmPC and has been observed in clinical trials and post-marketing surveillance. The presenting symptom of acute pancreatitis is severe, persistent abdominal pain that may radiate to the back and is often accompanied by nausea and vomiting — this requires urgent medical attention and Wegovy should not be restarted in patients who have had a confirmed pancreatitis episode associated with semaglutide use. Gallbladder disease, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), has also been reported more frequently in patients on semaglutide than in placebo groups in clinical trials — symptoms include right-sided upper abdominal pain, fever, and jaundice, and should be reported to a clinician promptly.

Heart rate increase has been observed with semaglutide treatment — a mean increase of approximately two to three beats per minute has been reported in clinical trials, though higher increases have been observed in some patients and clinically significant tachycardia has been reported as a reason for treatment discontinuation in some cases. Any significant or symptomatic increase in heart rate should be reported to a prescribing clinician promptly, and this effect warrants particular monitoring in patients with pre-existing cardiac conditions. Mood-related effects including depression and suicidal ideation have been subject to regulatory monitoring across the GLP-1 medication class, and while a direct causal link has not been established for semaglutide specifically, patients with a history of depression or suicidal ideation should discuss this with their prescribing clinician before starting Wegovy — and any significant changes in mood or mental health during treatment should be reported promptly. Hypoglycaemia risk is low with Wegovy used as monotherapy, but is meaningfully increased in patients taking concomitant sulphonylureas or insulin — this combination requires particularly careful clinical management and monitoring.

Who Should Not Take Wegovy?

Wegovy is not appropriate for all patients, and the contraindications and precautions set out in its approved UK Summary of Product Characteristics must be carefully assessed before prescribing. The formal contraindication in the current UK SmPC is hypersensitivity to semaglutide or its excipients. However, Wegovy is not recommended in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), as animal studies identified a potential association between GLP-1 receptor agonists and thyroid C-cell tumours — whether this translates to human risk remains uncertain, but prescribers exercise particular caution in these patients and a careful clinical discussion is essential before proceeding. Wegovy should not be used during pregnancy, as weight loss is not recommended during pregnancy and the effects of semaglutide on fetal development are not established — patients who are planning a pregnancy should discontinue Wegovy at least 2 months before attempting to conceive. Breastfeeding women should not take Wegovy as it is unknown whether semaglutide is excreted in human milk.

Beyond absolute contraindications, Wegovy requires particular caution and careful clinical assessment in patients with a history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, renal impairment, or significant cardiovascular disease. It is also important to consider potential interactions with other medications — semaglutide’s effects on gastric emptying can influence the absorption of orally administered medications, and this should be reviewed as part of the prescribing assessment. This breadth of contraindications and precautions underscores why a thorough, individualised clinical assessment before starting Wegovy is not optional but essential for safe use.

The Importance of Accessing Wegovy Safely

One of the most significant safety risks associated with Wegovy in the UK is not the medication itself but the circumstances in which some patients are accessing it — specifically, through unregulated online suppliers who provide it without a proper clinical assessment, without a valid prescription, and without any ongoing monitoring or support. Counterfeit or substandard semaglutide products obtained through these channels pose serious and direct safety risks, as their content, potency, and sterility cannot be verified. Even genuine semaglutide obtained without clinical oversight poses risks for patients with contraindications that have not been assessed, or who develop adverse effects without access to appropriate professional support. The MHRA has issued repeated warnings about the risks of purchasing weight loss injections from unregulated sources and continues to take enforcement action against illegal suppliers.

Accessing Wegovy through a GPhC-registered pharmacy with a properly regulated prescribing process — including a thorough initial clinical assessment, a prescription issued by a named registered prescriber, and ongoing monitoring throughout treatment — is the only way to ensure that the medication is being used safely and appropriately. The clinical assessment is not merely an administrative hurdle but a genuine safety mechanism that identifies contraindications, manages interactions, and establishes the baseline monitoring needed to support safe treatment. Any suspected counterfeit or substandard Wegovy should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Wegovy Safety in Special Populations

The safety of Wegovy has been studied in several specific patient populations, and understanding how it performs in these groups is an important part of forming an accurate overall picture of its safety profile. In patients with type 2 diabetes (studied in STEP 2), the safety profile was broadly consistent with that seen in non-diabetic populations, with the additional consideration of hypoglycaemia risk in those on concomitant glucose-lowering medications. In adolescents aged 12 to under 18 years with obesity (studied in STEP TEENS), the safety profile was similar to that in adults, though the long-term effects of semaglutide on growth, development, and endocrine function in this age group require ongoing monitoring. In older adults, the medication appears well-tolerated, though the potential for reduced renal function and polypharmacy interactions warrants particular attention during the clinical assessment process.

The SELECT trial’s findings in patients with established cardiovascular disease are particularly reassuring for this high-risk population — not only was semaglutide safe in over 17,000 participants with cardiovascular disease followed for more than three years, but it actively reduced the relative risk of major cardiovascular events by 20% — equivalent to an absolute risk reduction of approximately 1.5 percentage points — providing a compelling argument for its use in appropriately assessed patients with both obesity and cardiovascular risk. This cardiovascular benefit is distinct from and additional to the weight loss benefit, and represents a genuinely significant advance in the treatment of obesity-related cardiovascular risk.

Frequently Asked Questions

Here are the Wegovy safety questions the clinical team at J E Williamson Pharmacy in Bishops Stortford addresses most frequently with patients considering or currently on treatment.

Is Wegovy safe for long-term use?

The available long-term safety data for semaglutide is reassuring — the SELECT cardiovascular outcomes trial followed over 17,000 patients for more than three years and demonstrated a favourable safety profile alongside a 20% relative risk reduction in major cardiovascular events, equivalent to an absolute risk reduction of approximately 1.5 percentage points. Ongoing pharmacovigilance continues to monitor real-world safety, and current clinical evidence supports Wegovy’s use as a long-term treatment for eligible patients under appropriate clinical supervision.

Can Wegovy cause thyroid cancer?

Animal studies identified an association between GLP-1 receptor agonists and thyroid C-cell tumours, which is why Wegovy is not recommended in patients with a personal or family history of medullary thyroid carcinoma or MEN2 — the formal UK contraindication in the SmPC is hypersensitivity to semaglutide or its excipients, but MTC and MEN2 are treated as strong clinical precautions requiring careful discussion before any prescribing decision. The clinical relevance of the animal findings to humans has not been established, and no increased incidence of medullary thyroid carcinoma has been observed in the extensive clinical trial data to date — patients with concerns should discuss this specifically with their prescribing clinician.

Is Wegovy safe if I have heart disease?

The SELECT trial demonstrated that semaglutide not only appears safe in patients with established cardiovascular disease but actively reduces the risk of major cardiovascular events by 20% compared to placebo over more than three years of follow-up. However, individual cardiovascular circumstances vary significantly, and patients with heart disease should always undergo a thorough clinical assessment with their prescribing clinician before starting Wegovy to ensure it is appropriate for their specific cardiac profile.

What should I do if I experience side effects on Wegovy?

Most side effects on Wegovy, particularly the common gastrointestinal effects, are mild to moderate and improve with time and dietary adjustments — these can be managed with the support of your prescribing clinician or pharmacist without stopping treatment. However, symptoms suggesting pancreatitis (severe, persistent abdominal pain), gallbladder disease (right-sided upper abdominal pain, fever, or jaundice), significant allergic reactions, or severe mood changes should be reported to a clinician promptly and, in the case of severe abdominal pain, urgently.

Can Wegovy be taken safely alongside other medications?

Wegovy’s effects on gastric emptying can influence the absorption of other orally administered medications, and this should be reviewed as part of the prescribing assessment for any patient on regular medication. The most clinically significant interaction is with glucose-lowering medications such as sulphonylureas and insulin, where the combination meaningfully increases hypoglycaemia risk and requires careful clinical management and dose adjustment under the supervision of a prescribing clinician.

Is Wegovy safe to buy online?

Wegovy can be safely and legally purchased online in the UK, but only through a pharmacy registered with the General Pharmaceutical Council (GPhC) that requires a valid prescription from a named, registered prescriber following a thorough clinical assessment. Purchasing from unregulated online sources poses serious safety risks including exposure to counterfeit or substandard products, absence of clinical assessment, and no access to professional support — the MHRA has specifically warned against this practice and continues to take enforcement action against illegal suppliers.

Wegovy and Your Safety

Wegovy is a safe and effective weight loss treatment for appropriately assessed adults, backed by one of the most extensive clinical trial programmes ever conducted for a weight management medication and supported by long-term safety data that includes compelling cardiovascular benefit. Like all prescription medications, it carries recognised side effects and contraindications that require expert clinical assessment before treatment begins — and the safety of any treatment is inseparable from the quality of the clinical service through which it is accessed. At J E Williamson Pharmacy in Bishops Stortford, every Wegovy patient benefits from a thorough pre-treatment assessment, ongoing clinical monitoring, and the expert support needed to manage any side effects that arise and maximise the safety and effectiveness of their treatment throughout. Book now and start your Wegovy journey with the clinical rigour, professional care, and patient safety commitment that every patient deserves.